Drugs / OPGx-RDH12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07681778 | Sep 2026 → Dec 2032 expected | Leber congenital amaurosis | Opus Genetics, Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPGx-RDH12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07681778 ↗ |
| Route | Other | “via a cannula into the subretinal space” NCT07681778 ↗ |